Insulet Corporation (PODD)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $10.58B
Last updated: Nov 17, 2026 at 11:06 AM ET
Insulet Corporation (PODD) Stock Forecast
Analysts expect Insulet (PODD) to earn $6.77 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.30B. Of 26 analysts, 15 rate the stock Buy or Strong Buy, 11 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 26 ratings average 2.27, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 58% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 15.4% |
| Buy | 11 | 42.3% |
| Hold | 11 | 42.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 26
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 16.8% and revenue estimates rise 11.8%.
- Fiscal year ending Dec 31, 2026
- $6.77
- EPS consensus, revenue $3.30B
- Fiscal year ending Dec 31, 2027
- $7.91
- EPS consensus, revenue $3.69B
- Next report
- Feb 16, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $6.77 | $5.91 to $7.01 | 25 | $3.30B | $3.28B to $3.32B | 25 |
| Dec 31, 2027 | $7.91 | $5.58 to $8.42 | 25 | $3.69B | $3.54B to $3.73B | 25 |
Quarterly Estimates
The EPS consensus falls from $1.81 for the quarter ending Dec 31, 2026 to $1.66 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.81 | $1.57 to $2.08 | 27 | $919.43M | $858.28M to $985.95M | 26 |
| Mar 31, 2027 | $1.66 | $1.40 to $1.78 | 17 | $851.33M | $827.00M to $878.50M | 17 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 8 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 2 |
| Fiscal year ending Dec 31, 2027 | 1 | 5 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 4.2% from $6.50.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $6.77 | $6.51 | $6.51 | $6.50 | $6.50 | +4.1% |
| Fiscal year ending Dec 31, 2027 | $7.91 | $7.72 | $7.73 | $7.71 | $7.72 | +2.4% |
| Quarter ending Mar 31, 2027 | $1.66 | $1.63 | $1.64 | $1.62 | $1.63 | +1.8% |
Frequently Asked Questions About PODD
What is the PODD stock forecast?
Consensus analyst estimates put Insulet's EPS at $6.77 for the fiscal year ending Dec 31, 2026, on revenue of $3.30B. The consensus rating from 26 analysts is Buy.
How do analysts rate PODD stock?
Of 26 analysts covering Insulet, 4 rate it Strong Buy, 11 Buy, 11 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PODD next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $6.77, with estimates from $5.91 to $7.01 from 25 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $7.91, with estimates from $5.58 to $8.42 from 25 analysts.
What revenue do analysts expect from Insulet next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.30B, with estimates from $3.28B to $3.32B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.69B, with estimates from $3.54B to $3.73B.
How many analysts cover PODD?
26 analysts rate Insulet stock, and 25 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PODD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors